EP Patent

EP1851339B1 — Methods and compositions for detecting a drug resistant egfr mutant

Assigned to Memorial Sloan Kettering Cancer Center · Expires 2016-05-18 · 10y expired

What this patent protects

Patent listed against lazertinib-mesylate.

Drugs covered by this patent

Patent Metadata

Patent number
EP1851339B1
Jurisdiction
EP
Classification
—
Expires
2016-05-18
Drug substance claim
No
Drug product claim
No
Assignee
Memorial Sloan Kettering Cancer Center
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.